Lopacut: Uses, Dosage & Side Effects

What Is Lopacut and What Is It Used For?

Loperamide hydrochloride, the active ingredient in Lopacut, is a synthetic piperidine derivative that was first developed by Janssen Pharmaceutica in 1969 and has been in widespread clinical use for over five decades. It belongs to the pharmacological class of opioid receptor agonists, but unlike classic opioid analgesics such as morphine or codeine, loperamide is designed to act almost exclusively on the peripheral mu-opioid receptors located in the myenteric plexus of the large intestinal wall. This targeted peripheral action is the key to its effectiveness as an antidiarrheal agent without the sedative, analgesic, or euphoric effects that characterize centrally acting opioids.

The mechanism by which loperamide controls diarrhea involves several complementary pharmacological actions. First, it binds to mu-opioid receptors in the circular and longitudinal muscle layers of the intestinal wall, inhibiting the release of acetylcholine and prostaglandins. This reduces propulsive peristalsis – the coordinated muscle contractions that move intestinal contents forward – thereby increasing the transit time of material through the gastrointestinal tract. With a longer transit time, the intestinal mucosa has more opportunity to absorb water and electrolytes from the luminal contents, resulting in firmer and less frequent stools. Second, loperamide reduces the volume of fluid secreted into the intestinal lumen by acting on calmodulin-regulated chloride channels and by inhibiting voltage-dependent calcium channels in enterocytes. Third, loperamide increases the tone of the anal sphincter, which helps reduce feelings of urgency and the risk of fecal incontinence.

A critical feature of loperamide’s pharmacology is its inability to cross the blood–brain barrier in significant amounts at recommended therapeutic doses. This is because loperamide is a substrate for P-glycoprotein (P-gp), an efflux transporter protein expressed at the blood–brain barrier that actively pumps loperamide back into the bloodstream before it can enter the central nervous system. Additionally, loperamide undergoes extensive first-pass metabolism in the liver, primarily by the cytochrome P450 enzymes CYP3A4 and CYP2C8, resulting in a very low systemic bioavailability of approximately 0.3%. These pharmacokinetic properties ensure that at recommended doses, loperamide does not produce the central opioid effects – such as respiratory depression, sedation, or euphoria – that are associated with other opioids. However, it is important to note that at supratherapeutic doses, or when combined with P-glycoprotein inhibitors, loperamide can overcome these protective mechanisms and cause serious adverse effects, including life-threatening cardiac arrhythmias.

Lopacut is indicated for the symptomatic treatment of acute diarrhea in adults and adolescents aged 12 years and older. Acute diarrhea is defined by the World Health Organization (WHO) as the passage of three or more loose or liquid stools per day, or more frequently than is normal for the individual, lasting less than 14 days. Common causes include viral gastroenteritis (such as norovirus or rotavirus), food-borne illness, traveller’s diarrhea, medication side effects, and stress-related functional bowel disturbance. Lopacut provides rapid symptomatic relief by reducing stool frequency and improving stool consistency, but it does not treat the underlying cause of diarrhea. Therefore, it should be used as an adjunct to oral rehydration therapy, which remains the cornerstone of diarrhea management according to WHO, WGO, and other international guidelines.

Under medical supervision, loperamide may also be prescribed for the management of chronic diarrhea associated with conditions such as irritable bowel syndrome with predominant diarrhea (IBS-D), inflammatory bowel disease (IBD), short bowel syndrome, and radiation enteritis. In patients with an ileostomy, loperamide can help reduce the volume and frequency of ileostomy output, improving quality of life. In these chronic settings, the dosage is individually titrated by a physician to achieve the lowest effective dose that produces one to two formed stools per day.

What Should You Know Before Taking Lopacut?

Contraindications

There are several important situations in which Lopacut must not be used. Understanding these contraindications is essential for safe use of this medication. First, do not take Lopacut if you are allergic (hypersensitive) to loperamide hydrochloride or any of the other ingredients in the tablets. Signs of an allergic reaction may include skin rash, itching, swelling of the face or throat, difficulty breathing, or a sudden drop in blood pressure.

Lopacut should not be used as the primary treatment for acute dysentery, which is characterized by bloody stools and high fever. In acute dysentery, the diarrhea is typically caused by invasive bacterial pathogens such as Shigella, Salmonella, or Campylobacter, and reducing intestinal motility with loperamide may delay the clearance of the pathogen and worsen the infection. Similarly, Lopacut should not be used in patients with acute ulcerative colitis or pseudomembranous colitis (often associated with Clostridioides difficile infection following antibiotic use), as reducing peristalsis in these conditions can precipitate toxic megacolon, a potentially life-threatening complication.

Lopacut must not be used in cases where inhibition of peristalsis should be avoided due to the risk of significant sequelae, including ileus, megacolon, and toxic megacolon. It should also not be used when diarrhea is associated with conditions requiring specific treatment, such as cholera or other severe dehydrating diarrheal illnesses where oral or intravenous rehydration therapy is the primary intervention. Lopacut must not be used in children under 12 years of age without direct medical supervision.

Warnings and Precautions

Several important precautions should be observed when using Lopacut. Because diarrhea can cause significant fluid and electrolyte loss, treatment with loperamide should always be accompanied by appropriate fluid and electrolyte replacement. This is particularly important in young adults, the elderly, and debilitated individuals who may be more susceptible to dehydration. Oral rehydration solutions (ORS) are recommended by the WHO for all patients with diarrhea.

If symptoms do not improve within 48 hours of starting treatment, Lopacut should be discontinued and a healthcare professional consulted. Persistent diarrhea beyond 48 hours may indicate an underlying condition requiring diagnostic investigation, such as a bacterial or parasitic infection, inflammatory bowel disease, or malabsorption syndrome. Development of fever, blood in the stools, or abdominal distension during treatment should prompt immediate medical evaluation.

Patients with hepatic impairment (liver disease) should use Lopacut with caution, as loperamide is extensively metabolized by the liver. In patients with liver dysfunction, reduced first-pass metabolism can lead to higher systemic concentrations of loperamide, increasing the risk of central nervous system effects. Such patients should be monitored for signs of toxicity and may require dose adjustments under medical guidance.

Patients with AIDS-related diarrhea should use loperamide under close medical supervision. In immunocompromised patients, diarrhea may be caused by opportunistic infections that require specific antimicrobial therapy. If abdominal distension or other signs of ileus develop, loperamide should be discontinued immediately.

Pregnancy and Breastfeeding

The safety of loperamide during pregnancy has not been established through adequate, well-controlled studies in pregnant women. Animal reproduction studies have not demonstrated teratogenic effects at therapeutic doses, but high doses in animal studies have been associated with reduced fetal survival. As a precautionary measure, Lopacut should not be used during the first trimester of pregnancy. During the second and third trimesters, it should only be used if the expected benefit to the mother outweighs the potential risk to the fetus, and only under medical supervision. Non-pharmacological measures such as oral rehydration therapy should be considered as the first-line approach to managing diarrhea during pregnancy.

Small amounts of loperamide have been detected in human breast milk, though the concentrations are very low. A study evaluating loperamide excretion in breast milk found that maternal doses resulted in negligible amounts reaching the nursing infant, with calculated infant doses being less than 0.1% of the maternal weight-adjusted dose. Short-term use of loperamide at recommended doses is generally considered compatible with breastfeeding by most expert bodies, including the American Academy of Pediatrics. However, it is advisable to consult a healthcare professional before using Lopacut while breastfeeding, particularly for prolonged or repeated use.

How Does Lopacut Interact with Other Drugs?

While loperamide has a relatively favorable drug interaction profile owing to its low systemic bioavailability, several clinically important interactions should be considered. The primary pharmacokinetic interactions involve the inhibition of the cytochrome P450 enzymes (CYP3A4 and CYP2C8) responsible for loperamide metabolism and the P-glycoprotein (P-gp) efflux transporter that prevents loperamide from crossing the blood–brain barrier.

When loperamide is co-administered with inhibitors of CYP3A4, CYP2C8, or P-glycoprotein, its plasma concentrations can increase significantly. This is clinically relevant because elevated systemic loperamide levels can lead to enhanced exposure of the heart and central nervous system to the drug, potentially causing QT prolongation, cardiac arrhythmias, and central opioid effects. Patients taking any of the medications listed in the interaction table below should use loperamide only under medical guidance and at the lowest effective dose.

Major Interactions

Minor Interactions

It is important to note that at standard recommended doses, loperamide has very low systemic bioavailability and the clinical significance of most pharmacokinetic interactions is limited. However, in patients who intentionally or accidentally take higher-than-recommended doses, these interactions become clinically significant and potentially dangerous. Patients should always inform their healthcare provider and pharmacist about all medications they are taking, including prescription drugs, over-the-counter products, and herbal supplements.

What Is the Correct Dosage of Lopacut?

The dosage of Lopacut depends on the indication, the patient’s age, and whether treatment is supervised by a healthcare professional. The tablets should be swallowed whole with a glass of water and can be taken with or without food. The goal of treatment is to achieve the lowest effective dose that produces one to two formed stools per day.

Adults

Children

Elderly

No specific dose adjustment is required in elderly patients. However, elderly individuals may be more susceptible to the effects of dehydration caused by diarrhea and should be closely monitored for signs of fluid and electrolyte depletion. Elderly patients with hepatic impairment should use loperamide with particular caution due to the potential for reduced drug metabolism and increased systemic exposure. Low starting doses and careful titration are recommended in frail elderly patients.

Missed Dose

Lopacut is taken on an as-needed basis after loose stools, rather than on a fixed schedule. Therefore, the concept of a “missed dose” does not typically apply. Simply take 2 mg (1 tablet) after your next loose stool if needed. Do not take a double dose to make up for a forgotten dose, and do not exceed the maximum recommended daily dose.

Overdose

Overdose of loperamide is a serious medical emergency. Symptoms of overdose may include severe constipation, urinary retention, paralytic ileus, central nervous system depression (including drowsiness, miosis, muscular hypertonia, respiratory depression, and impaired coordination), and cardiac toxicity (including QT prolongation, torsades de pointes, wide QRS complexes, and cardiac arrest). The cardiac effects are of particular concern, as loperamide at high doses can block cardiac sodium and potassium channels (including hERG channels), leading to potentially fatal arrhythmias.

In the event of suspected overdose, seek emergency medical attention immediately. Treatment is supportive and may include the administration of naloxone as an opioid antagonist. Because the duration of action of loperamide is longer than that of naloxone (1–3 hours), repeated doses of naloxone may be necessary. Patients should be monitored for at least 48 hours to detect any cardiac or central nervous system effects. Activated charcoal may be administered if the patient presents within one hour of ingestion.

What Are the Side Effects of Lopacut?

Like all medicines, Lopacut can cause side effects, although not everybody gets them. The side effects of loperamide are generally mild when used at recommended doses and typically resolve upon discontinuation of the medication. The most commonly reported adverse effects are related to the drug’s pharmacological action of slowing intestinal motility.

The frequency of side effects is classified according to the following standard convention used by the European Medicines Agency (EMA): very common (affects more than 1 in 10 people), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), rare (1 in 1,000 to 1 in 10,000), and not known (frequency cannot be estimated from available data).

It is important to distinguish between the side effects that occur at recommended therapeutic doses and the severe adverse effects associated with overdose or intentional misuse. At standard recommended doses, the most clinically significant side effect is constipation, which occurs because the drug’s mechanism of action – slowing intestinal transit – can overshoot its intended effect. Constipation is typically dose-dependent and resolves when the medication is discontinued or the dose is reduced.

Severe allergic reactions (anaphylaxis) to loperamide are extremely rare but have been reported in post-marketing surveillance. Symptoms may include sudden onset of skin rash, itching, swelling of the face, tongue, or throat, difficulty breathing, and a rapid drop in blood pressure. If you experience any signs of a severe allergic reaction, stop taking Lopacut immediately and seek emergency medical care.

The cardiac adverse effects (QT prolongation, ventricular tachycardia including torsades de pointes, and cardiac arrest) have primarily been reported in association with doses greatly exceeding the recommended maximum, often in the context of intentional misuse or abuse. The U.S. FDA and EMA have issued safety warnings emphasizing that loperamide should never be taken in doses higher than recommended, as this can cause serious and potentially fatal cardiac events. Patients with pre-existing cardiac conditions or those taking other QT-prolonging medications are at increased risk.

How Should You Store Lopacut?

Proper storage of medications is essential to maintain their effectiveness and safety throughout their shelf life. Lopacut 2 mg film-coated tablets should be stored at room temperature, not exceeding 25°C (77°F). The tablets should be kept in their original packaging (blister pack or container) to protect them from moisture and light, as exposure to humidity or direct sunlight can degrade the active ingredient and reduce the medication’s effectiveness over time.

Do not store Lopacut in the bathroom, near a kitchen sink, or in other areas with high humidity. Avoid storing the medication in a car or other location where it may be exposed to extreme temperatures, particularly excessive heat. If the tablets change color, become discolored, or appear damaged in any way, do not use them.

Keep Lopacut out of the sight and reach of children. Accidental ingestion of loperamide by children can cause serious adverse effects, including central nervous system depression and respiratory depression. In the event of accidental ingestion by a child, seek emergency medical attention immediately.

Do not use Lopacut after the expiration date (marked as “EXP”) printed on the packaging. The expiration date refers to the last day of that month. Do not dispose of medications by flushing them down the toilet or pouring them into drains. Ask your pharmacist about local medication take-back programs or proper disposal methods in accordance with local regulations to protect the environment.

What Does Lopacut Contain?

Active Ingredient

Each Lopacut film-coated tablet contains 2 mg of loperamide hydrochloride, which corresponds to approximately 1.74 mg of loperamide base. Loperamide hydrochloride is a white to slightly yellow powder that is practically insoluble in water. Its chemical name is 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutyramide monohydrochloride, and its molecular formula is C₂₉H₃₃ClN₂O₂·HCl with a molecular weight of 513.50 g/mol.

Inactive Ingredients (Excipients)

In addition to the active ingredient, each Lopacut tablet contains excipients that are essential for the manufacturing process, structural integrity, and stability of the tablet. Typical excipients found in loperamide film-coated tablets include:

• Tablet core: Lactose monohydrate, maize starch (corn starch), pregelatinized starch, talc, magnesium stearate
• Film coating: Hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171), macrogol (polyethylene glycol)

Patients with known lactose intolerance should be aware that the tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. Patients with known hypersensitivity to any of the excipients should not take this medication.

Lopacut tablets are typically small, round or oval, white to off-white film-coated tablets. The film coating provides a smooth surface that makes the tablet easier to swallow, protects the core from moisture, and may help mask the taste of the active ingredient. The exact appearance and markings may vary by manufacturer and batch.